TissueScan, Breast Cancer cDNA Array I

Snippet: The endometrial cancer cDNA array, (ORIGENE, EDRT102) and the breast cancer cDNA array (ORIGENE, BCRT101) were used to validate the PBRM1 E27 AS patterns

Snippet: 1b, c). As mRNA expression data were not available for these cohorts, INPP4B mRNA expression was examined using Tissue Scan Breast Cancer cDNA arrays I-IV (OriGene) of 130 primary human breast cancers and 16 normal breast tissues (Fig. 1c);Breast cancer cDNA arrays (176 breast cancers and 16 tumor adjacent normal breast tissues) were purchased from OriGene (BCRT101, BCRT102, BCRT103, and BCRT104)

Snippet: To assess Xv1 expression level in normal breast tissues and in tumors at different breast cancer stages, qPCR was performed in Breast Cancer cDNA Array I (Origene, BCRT101) using a CFX96 Touch Real-Time PCR Detection System (Bio-rad)

Snippet: breast tissue samples. Briefly, TissueScan Cancer Survey Tissue qPCR panels BCRT101, BCRT102, BCRT103 and BCRT104 were arrayed onto a single 384‑well reaction plate by OriGene Technologies, Inc. Data are expressed

Snippet: All cell culture materials and classical chemotherapeutic drugs were from Sigma-Aldrich Ltd (Gillingham, UK). TissueScan qPCR Breast Cancer Disease Panels I, II, and IV (BCRT101, BCRT102, BCRT104) were purchased from OriGene Technologies